OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Tuesday

OnKure Therapeutics (NASDAQ:OKUR) is expected to be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect OnKure Therapeutics to announce earnings of ($0.58) per share and revenue of $0.1670 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.37). On average, analysts expect OnKure Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

OnKure Therapeutics Stock Up 4.6%

OnKure Therapeutics stock traded up $0.18 during trading on Tuesday, hitting $4.21. The stock had a trading volume of 85,804 shares, compared to its average volume of 262,791. The stock’s 50 day moving average is $4.26 and its two-hundred day moving average is $3.81. OnKure Therapeutics has a 1 year low of $1.91 and a 1 year high of $5.38. The stock has a market cap of $169.88 million, a price-to-earnings ratio of -0.97 and a beta of 0.30.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently added to or reduced their stakes in OKUR. XTX Topco Ltd purchased a new position in OnKure Therapeutics during the second quarter worth about $25,000. Jane Street Group LLC bought a new position in OnKure Therapeutics in the 4th quarter worth about $56,000. Hsbc Holdings PLC purchased a new stake in shares of OnKure Therapeutics in the 4th quarter valued at about $58,000. Rangeley Capital LLC purchased a new stake in shares of OnKure Therapeutics in the 2nd quarter valued at about $71,000. Finally, Barclays PLC boosted its position in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after acquiring an additional 26,621 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on OKUR shares. JonesTrading downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. HC Wainwright reduced their price target on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research report on Monday, July 20th. Weiss Ratings lowered OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, OnKure Therapeutics presently has a consensus rating of “Hold” and an average target price of $21.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.